The Latest Breaking News from Genmab

Genmab stock slumped Wednesday after the Danish biotech announced it will buy privately held ProfoundBio for $1.8 billion.

The biotechnology industry is booming thanks to growing demand for innovative healthcare solutions, favorable government initiatives, and several scientific breakthroughs. Thus, quality biotech stocks Genmab (GMAB), Halozyme Therapeutics (HALO), and Vertex Pharmaceuticals (VRTX) could be ideal buys for substantial profits. Read more….

Here's a roundup of top developments in the biotech space over the last 24 hours:

Analysts have provided the following ratings for Genmab (NASDAQ:GMAB) within the last quarter:

Within the last quarter, Genmab (NASDAQ:GMAB) has observed the following analyst ratings:

Upgrades

Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV) 

Johnson & Johnson's (NYSE:JNJ) Janssen has won an arbitration against Genmab A/S (NASDAQ:GMAB) on two matters related to their licensing pact for multiple myeloma drug Darzalex (daratumumab). The first issue around daratumumab arose because Janssen announced a deal with Halozyme Therapeutics Inc (NASDAQ: HALO) to develop a subcutaneous formulation of daratumumab. According to Janssen, Genmab must share…

Here's a roundup of top developments in the biotech space over the last 24 hours.